Financial Performance - In 2022, the company achieved a total revenue of CNY 195.13 million, with overseas sales accounting for 90.95% of total revenue, amounting to CNY 177.48 million[16]. - The company's operating revenue for 2022 was CNY 195,132,408.42, representing a year-on-year increase of 1.66% compared to CNY 191,946,299.04 in 2021[31]. - The net profit attributable to shareholders for 2022 was CNY 40,301,539.44, a significant increase of 76.13% from CNY 22,881,399.64 in 2021[31]. - The gross profit margin improved to 46.38% in 2022, up from 37.59% in 2021[31]. - Hearing aid revenue accounted for 91.65% of total revenue, with a year-on-year growth of 14.49% to 178.84 million yuan[46]. - The company reported a net profit growth rate of 80.39% in 2022 compared to a decline of 45.49% in 2021[35]. - The basic earnings per share for 2022 was CNY 0.82, reflecting a growth of 36.67% from CNY 0.60 in 2021[31]. - The cash flow from operating activities for 2022 was CNY 27,362,364.11, an increase of 8.47% from CNY 25,225,648.78 in 2021[34]. Research and Development - The company invested 15.61 million yuan in R&D, marking a 347.51% increase, with R&D expenses constituting 8.00% of total revenue[47]. - The company holds 140 patents and 8 copyrights, including 5 invention patents, demonstrating strong innovation capabilities[42]. - The company increased its R&D personnel from 45 to 62, with a higher proportion of employees engaged in R&D activities, rising from 14.24% to 16.40%[92]. - The company is actively developing digital hearing aids to align with market trends towards OTC, intelligent, professional, and personalized products[114]. - In 2022, the company's R&D investment reached a record high of 8.00% of total revenue, with plans to further increase R&D efforts in 2023, particularly for OTC hearing aids and HCP hearing aids[114]. Market Expansion and Sales - The company has established partnerships with major international retailers, including Walmart and Carrefour, enhancing its market presence[42]. - The company is focused on developing OTC hearing aids, which are expected to create new market opportunities and increase penetration rates[50]. - The company plans to enhance its overseas business development, particularly in the U.S. OTC market, following the easing of COVID-19 restrictions[111]. - The company plans to enhance market expansion efforts, focusing on increasing sales scale in both domestic and international markets, particularly in the Asia-Pacific, Europe, and the Middle East[113]. - The company has established three operational stores to enhance domestic sales and reduce reliance on overseas markets[120]. Corporate Governance and Compliance - The company is addressing risks related to governance and control by implementing internal control measures and enhancing its governance structure[117]. - The company has publicly disclosed that there are no false records or misleading statements in its financial reporting[143]. - The company has committed to eliminating all illegal occupation of funds and guarantees from the company and its subsidiaries[140]. - The company has established measures to address any potential economic losses resulting from breaches of competition commitments[145]. - The company will ensure effective management of raised funds, adhering to regulatory requirements and internal management systems[162]. Shareholder Commitments and Equity - The 2022 equity incentive plan granted a total of 675,000 restricted shares and 945,000 stock options to directors, senior management, and core employees[135]. - The company's share capital increased from 48.6 million shares to 49.275 million shares due to the implementation of the equity incentive plan[136]. - Major shareholders have pledged not to transfer or manage their shares for 12 months post-IPO, with a maximum of 25% of their shares allowed for transfer annually during their tenure[148]. - The company has committed to a profit distribution policy that prioritizes cash dividends, with a minimum of 10% of distributable profits to be distributed in cash annually, and a cumulative cash distribution of at least 30% of the average annual distributable profits over the last three years[169]. - The company will review its shareholder return plan at least every three years after listing on the selected tier, considering changes in circumstances or policies[171]. Investment and Asset Management - The company raised a total of RMB 210 million through a public offering, with a net amount of RMB 190.14 million after expenses[195]. - During the reporting period, the company used RMB 132.18 million of the raised funds, with a remaining balance of RMB 7.82 million as of December 31, 2022[197]. - The funds raised are allocated for the construction of a smart medical product production base and an intelligent hearing aid design research center[195]. - The total amount of raised funds invested to date is approximately ¥185.12 million, indicating a utilization rate of 95.62%[199]. - The company utilized part of the idle raised funds for cash management, with a total purchase amount of ¥12.5 million in structured deposits[199]. Social Responsibility - The company engaged in a series of successful public welfare activities in collaboration with Ruyi Tree in 2022[9]. - The company actively participated in social responsibility initiatives, providing free hearing health checks to 16,000 individuals and distributing 4,550 hearing aids in rural areas[106].
锦好医疗(872925) - 2022 Q4 - 年度财报